CA2484100A1 - Novel biomaterials, their preparation and use - Google Patents
Novel biomaterials, their preparation and use Download PDFInfo
- Publication number
- CA2484100A1 CA2484100A1 CA002484100A CA2484100A CA2484100A1 CA 2484100 A1 CA2484100 A1 CA 2484100A1 CA 002484100 A CA002484100 A CA 002484100A CA 2484100 A CA2484100 A CA 2484100A CA 2484100 A1 CA2484100 A1 CA 2484100A1
- Authority
- CA
- Canada
- Prior art keywords
- precipitate
- component
- composition
- pharmaceutical composition
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012620 biological material Substances 0.000 title abstract 2
- 239000002244 precipitate Substances 0.000 claims abstract 37
- 239000000203 mixture Substances 0.000 claims abstract 25
- 238000000034 method Methods 0.000 claims abstract 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 9
- 125000000129 anionic group Chemical group 0.000 claims abstract 8
- 239000012736 aqueous medium Substances 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 102000004190 Enzymes Human genes 0.000 claims abstract 2
- 108090000790 Enzymes Proteins 0.000 claims abstract 2
- 239000003905 agrochemical Substances 0.000 claims abstract 2
- 239000003086 colorant Substances 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- 239000000575 pesticide Substances 0.000 claims abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- -1 cationic phospholipid Chemical class 0.000 claims 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 claims 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000030 antiglaucoma agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- 229960001574 benzoxonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019837 monoammonium phosphate Nutrition 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 150000003410 sphingosines Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Abstract
The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component , which precipitate is obtainable by a process including the following steps: contacting the anionic polymeric component and an cylcodextrin component in an aqueous medium, and adding to the mixture obtained in step 1 said amphiphili c ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cycxlodextrin component. Both type s of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulation s suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compound s, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.< /SDOAB>
Claims (28)
1. A precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps:
1. contacting the anionic polymeric component and a cyclodextrin component in an aqueous medium, and
1. contacting the anionic polymeric component and a cyclodextrin component in an aqueous medium, and
2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate.
2. A precipitate according to claim 1 additionally comprising said cyclodextrin component.
2. A precipitate according to claim 1 additionally comprising said cyclodextrin component.
3. A precipitate according to claim 1 or 2 additionally comprising one or more further component other than said cyclodextrin component which is added in course of step 1 and/or 2 of said process.
4. A precipitate according to claim 3 wherein said one or more other component is selected from pharmaceutically active agents, pesticides, agrochemicals, colorants, diagnostics, enzymes and foodstuffs.
5. A precipitate according to anyone of claims 1 to 4, wherein the anionic polymeric component is a member of the group consisting of hyaluronic acid, carboxymethyl cellulose, carboxymethyl starch, alginic acid, polyacrylic-acid-type polymeric components, pectin, xanthan gum, tragacantha gum, a water soluble salt of one of said components and a mixture of two or more of said members.
6. A precipitate according to anyone of claims 1 to 5, wherein said amphiphilic ammonium-type component comprises a cationic surfactant.
7. A precipitate according to anyone of claims 1 to 6, wherein said amphiphilic onium type component is selected from the group consisting of benzalkonium-chloride, benzoxonium-chloride, cetyl-pyridinium chloride, cetyltrimethylammonium bromide, cetyldimethyl(2-hydroxyethyl)ammonium dihydrogen phosphate (Luviquat® Mono CP), cocamidopropyl-N,N,N,trimethyl-glycine, acyl carnitines, in particular palmitoyl carnitine, sodium cocyl glutamate and mixtures of one or more members of said group.
8. A precipitate according to anyone of claims 1 to 7, wherein said amphiphilic onium type component comprises a cationic phospholipid.
9. A precipitate according to claim 8, wherein the cationic phospholipid is selected from lysophosphatidyl-choline compounds, phosphatidyl choline compounds, sphingomyelin, sphingosine derivatives and mixtures thereof.
10. A precipitate according to anyone of claims 1 to 9, wherein the cyclodextrin component is selected from alfa-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and mixtures thereof.
11. A precipitate according to claim 4, wherein the one or more further components comprise a pharmaceutically active agent.
12. A precipitate according to claim 11, wherein the pharmaceutically active agent is selected from the group consisting of steroids, prostanoids, nitric-oxide prodrugs, antihistamines, antibiotics, cytostatic agents, antivirals, peptide hormones, local anesthetics, antiglaucoma agents, antiinflammatory agents, antihypertensives, antiangiogenic agents and suitable combinations thereof.
13. A process for manufacturing a precipitate according to anyone of claims 1 to 12, wherein .cndot. the anionic polymeric component, the cyclodextrin component and further components comprised in said precipitate which are soluble in water are dissolved in an aqueous medium to form a first composition;
.cndot. the amphiphilic component and further components comprised in said precipitate which are insoluble in water are blended with a suitable liquid carrier, preferably an aqueous medium, to form a second composition, and .cndot. said first and second composition are blended to form said precipitate.
.cndot. the amphiphilic component and further components comprised in said precipitate which are insoluble in water are blended with a suitable liquid carrier, preferably an aqueous medium, to form a second composition, and .cndot. said first and second composition are blended to form said precipitate.
14. A process according to claim 13, wherein the precipitate is brought into a desired shape.
15. A process according to claim 13 including a treatment of a non-liquid carrier for coating it with said first composition and a subsequent treatment of the so-treated carrier with said second composition for forming a coating of said precipitate on said carrier.
16. A pharmaceutical composition comprising a precipitate according to claim 11 or 12.
17. A pharmaceutical composition according to claim 16, which is a depot formulation.
18. A medical device comprising a precipitate according to claim 11 or 12.
19. A medical implant or insert according to claim 18.
20. A kit for administering a pharmaceutical composition according to claim 16 or 17 to a subject by simultaneous or preferably by consecutive administration of parts of said composition to said subject thereby forming the composition in situ at the place of administration, which kit comprises two or more than two partial compositions, each comprising one or more of the components of said pharmaceutical composition, whereby the components intended to form the precipitate are present in said compositions for consecutive or simultaneous administration in amounts effective to form the precipitate.
21. A kit according to claim 20 comprising .cndot. a first composition comprising the anionic polymeric component, the cyclodextrin component and the further components comprised in said precipitate which are soluble in water, dissolved in an aqueous medium; and .cndot. a second composition comprising the amphiphilic component and components comprised in said precipitate which are insoluble in water, blended with a suitable liquid carrier, preferably an aqueous medium.
22. A kit according to claim 20 or 21 adjusted to a subcutaneous or intramuscular administration of the pharmaceutical composition.
23. A kit according to claim 20 or 21 adjusted to the administration of the pharmaceutical composition onto wounds, skin or other solid surfaces by spraying.
24. A method of administering a pharmaceutically active compound to a subject in need thereof, comprising the administration of a pharmaceutical composition according to claim 16 or 17 comprising said pharmaceutically active compound.
25. A method for administering a pharmaceutical composition according to claim 16 or 17 to a subject including the simultaneous or preferably consecutive administration of two or more than two partial compositions, each comprising one or more of the components of said pharmaceutical composition, thereby forming the pharmaceutical composition in situ at the place of administration, wherein the components intended to form the precipitate are present in said partial compositions in amounts effective to form the precipitate when contacted with one another.
26. A method according to claim 25 including the simultaneous or preferably consecutive administration of a first composition comprising the anionic polymeric component, the cyclodextrin component and the further components comprised in said precipitate which are soluble in water, dissolved in an aqueous medium; and a second composition comprising the amphiphilic component and components comprised in said precipitate which are insoluble in water, blended with a suitable liquid carrier, preferably an aqueous medium.
27. A method according to claim 25 or 26 wherein the partial compositions are subcutaneously or intramuscularly injected in the subject.
28. A method according to claim 25 or 26 wherein the partial compositions are administered onto wounds, skin or other solid surfaces, preferably by spraying.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02008809 | 2002-04-19 | ||
| EP02008809.2 | 2002-04-19 | ||
| PCT/EP2003/004076 WO2003089008A1 (en) | 2002-04-19 | 2003-04-17 | Novel biomaterials, their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2484100A1 true CA2484100A1 (en) | 2003-10-30 |
| CA2484100C CA2484100C (en) | 2012-01-03 |
Family
ID=29225593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2484100A Expired - Fee Related CA2484100C (en) | 2002-04-19 | 2003-04-17 | Novel biomaterials, their preparation and use |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20050163853A1 (en) |
| EP (1) | EP1499361B1 (en) |
| JP (1) | JP4648632B2 (en) |
| KR (1) | KR101121675B1 (en) |
| CN (1) | CN1646171B (en) |
| AU (1) | AU2003224099B2 (en) |
| BR (1) | BR0309340A (en) |
| CA (1) | CA2484100C (en) |
| CO (1) | CO5611168A2 (en) |
| ES (1) | ES2392964T3 (en) |
| HK (1) | HK1073070A1 (en) |
| IL (1) | IL164627A (en) |
| MX (1) | MXPA04010325A (en) |
| NO (1) | NO20044979L (en) |
| NZ (1) | NZ535810A (en) |
| PL (1) | PL215579B1 (en) |
| PT (1) | PT1499361E (en) |
| RU (1) | RU2321597C2 (en) |
| WO (1) | WO2003089008A1 (en) |
| ZA (1) | ZA200407794B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| WO2005072701A1 (en) * | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| WO2006011044A1 (en) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Amorphous cyclodextrin compositions |
| US8246949B2 (en) * | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
| SI1787658T1 (en) | 2005-11-10 | 2012-07-31 | Chemi Spa | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
| JP2009186445A (en) * | 2008-02-08 | 2009-08-20 | Arkray Inc | Method of analyzing hemoglobin by capillary electrophoresis, and reagent used for it |
| EP2060912B1 (en) * | 2006-09-04 | 2014-10-01 | National Institute of Advanced Industrial Science and Technology | Method for analysis of sample by capillary electrophoresis |
| US20100155242A1 (en) * | 2006-09-04 | 2010-06-24 | Arkray, Inc. | Method of Analyzing a Sample by Capillary Electrophoresis |
| WO2008029685A1 (en) * | 2006-09-04 | 2008-03-13 | National Institute Of Advanced Industrial Science And Technology | Method for analysis of sample by capillary electrophoresis |
| WO2010097700A1 (en) * | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8389558B2 (en) * | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) * | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| EP3513660A1 (en) | 2010-03-13 | 2019-07-24 | Eastpond Laboratories Limited | Fat-binding compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| US20120171184A1 (en) | 2010-12-31 | 2012-07-05 | Lajos Szente | Cellular hydration compositions |
| WO2012090018A1 (en) | 2010-12-31 | 2012-07-05 | Eastpond Laboratories Limited | Cellular hydration compositions containing cyclodextrins |
| EP2672828B1 (en) * | 2011-02-10 | 2015-04-29 | Unilever N.V. | Antimicrobial composition |
| BR112014017675B1 (en) | 2012-01-18 | 2021-06-22 | Surmodics, Inc | COATING FOR A LUBRICATING MEDICAL DEVICE WITH LOW PARTICULATE CONTENT, MEDICAL DEVICE AND METHOD OF PRODUCTION |
| EP3569226A1 (en) * | 2012-12-04 | 2019-11-20 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| AU2014265275B2 (en) * | 2013-05-17 | 2019-10-03 | Marquette University | Composite materials containing structural polysaccharides and macrocyclic compounds formed from ionic liquid compositions |
| JP5673756B2 (en) * | 2013-08-20 | 2015-02-18 | 東洋紡株式会社 | Medical materials |
| RU2597085C2 (en) * | 2013-11-07 | 2016-09-10 | Федеральное государственное бюджетное учреждение науки Институт биологии моря им. А.В. Жирмунского Дальневосточного отделения Российской академии наук (ИБМ ДВО РАН) | Implanted matrix material for regenerative medicine and method of its production (versions) |
| EP3313364B1 (en) | 2015-06-24 | 2019-10-23 | Kao Germany GmbH | Hair treatment process |
| US10342898B2 (en) * | 2015-12-29 | 2019-07-09 | Surmodics, Inc. | Lubricious coatings with surface salt groups |
| US11174447B2 (en) | 2015-12-29 | 2021-11-16 | Surmodics, Inc. | Lubricious coatings with surface salt groups |
| EP4132294A1 (en) | 2020-04-06 | 2023-02-15 | Eastpond Laboratories Limited | Compositions for promoting cellular hydration |
| CN114344557A (en) * | 2022-01-10 | 2022-04-15 | 山东万容生物科技有限公司 | Hydrocolloid dressing containing cyclodextrin and preparation method thereof |
| WO2023212740A1 (en) * | 2022-04-29 | 2023-11-02 | Drexel University | Surfactant-impregnated mof-coated fabric for antimicrobial applications |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE670837A (en) * | 1964-10-14 | 1966-01-31 | ||
| JPS61251616A (en) * | 1985-04-30 | 1986-11-08 | Agency Of Ind Science & Technol | Method for controlling amount of solute to be released |
| JPS6416728A (en) * | 1987-07-07 | 1989-01-20 | Santen Pharmaceutical Co Ltd | Aqueous preparation |
| JPH03234770A (en) * | 1990-02-09 | 1991-10-18 | Nippon Shokubai Kagaku Kogyo Co Ltd | Manufacture of gel responsive to electrical stimulus |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| SE9303627D0 (en) * | 1993-11-03 | 1993-11-03 | Kabi Pharmacia Ab | Method and means for the prevention of cataract |
| JPH08134134A (en) * | 1994-11-09 | 1996-05-28 | Nippon Shokubai Co Ltd | Method for drying granular hydrous gel polymer |
| JP3297969B2 (en) * | 1994-12-26 | 2002-07-02 | ライオン株式会社 | Eye drops |
| TW434023B (en) * | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| JPH0995413A (en) * | 1995-09-29 | 1997-04-08 | Shiseido Co Ltd | Preparation for external use for skin |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
| EP1144456A3 (en) * | 1999-01-12 | 2002-09-11 | Vito-Mannan Polysaccharide L.L.C. | Method of isolating mucilaginous polysaccharides and uses thereof |
| JP2001318350A (en) * | 2000-05-11 | 2001-11-16 | Lion Corp | Solution for contact lens |
| DE60130332T2 (en) * | 2000-05-15 | 2008-05-29 | The Procter & Gamble Company, Cincinnati | COMPOSITIONS CONTAINING CYCLODEXTRIN |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| PE20020146A1 (en) * | 2000-07-13 | 2002-03-31 | Upjohn Co | OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR |
| WO2002026728A2 (en) * | 2000-09-28 | 2002-04-04 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
-
2003
- 2003-04-17 NZ NZ535810A patent/NZ535810A/en not_active IP Right Cessation
- 2003-04-17 US US10/511,075 patent/US20050163853A1/en not_active Abandoned
- 2003-04-17 EP EP03720497A patent/EP1499361B1/en not_active Expired - Lifetime
- 2003-04-17 MX MXPA04010325A patent/MXPA04010325A/en active IP Right Grant
- 2003-04-17 KR KR1020047016698A patent/KR101121675B1/en not_active IP Right Cessation
- 2003-04-17 PL PL371595A patent/PL215579B1/en unknown
- 2003-04-17 RU RU2004133887/04A patent/RU2321597C2/en not_active IP Right Cessation
- 2003-04-17 WO PCT/EP2003/004076 patent/WO2003089008A1/en active Application Filing
- 2003-04-17 ES ES03720497T patent/ES2392964T3/en not_active Expired - Lifetime
- 2003-04-17 AU AU2003224099A patent/AU2003224099B2/en not_active Ceased
- 2003-04-17 CN CN038088592A patent/CN1646171B/en not_active Expired - Fee Related
- 2003-04-17 CA CA2484100A patent/CA2484100C/en not_active Expired - Fee Related
- 2003-04-17 BR BR0309340-9A patent/BR0309340A/en not_active IP Right Cessation
- 2003-04-17 JP JP2003585759A patent/JP4648632B2/en not_active Expired - Fee Related
- 2003-04-17 PT PT03720497T patent/PT1499361E/en unknown
-
2004
- 2004-09-28 ZA ZA200407794A patent/ZA200407794B/en unknown
- 2004-10-14 IL IL164627A patent/IL164627A/en not_active IP Right Cessation
- 2004-10-26 CO CO04107397A patent/CO5611168A2/en active IP Right Grant
- 2004-11-16 NO NO20044979A patent/NO20044979L/en not_active Application Discontinuation
-
2005
- 2005-07-07 HK HK05105740.7A patent/HK1073070A1/en unknown
-
2008
- 2008-07-24 US US12/178,934 patent/US20080299166A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/281,033 patent/US20120040901A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003224099B2 (en) | 2006-11-09 |
| JP2005529879A (en) | 2005-10-06 |
| CN1646171A (en) | 2005-07-27 |
| RU2321597C2 (en) | 2008-04-10 |
| US20120040901A1 (en) | 2012-02-16 |
| NO20044979L (en) | 2004-11-16 |
| US20080299166A1 (en) | 2008-12-04 |
| ZA200407794B (en) | 2006-02-22 |
| MXPA04010325A (en) | 2005-06-08 |
| AU2003224099A1 (en) | 2003-11-03 |
| JP4648632B2 (en) | 2011-03-09 |
| BR0309340A (en) | 2005-03-08 |
| IL164627A0 (en) | 2005-12-18 |
| HK1073070A1 (en) | 2005-09-23 |
| CA2484100C (en) | 2012-01-03 |
| PT1499361E (en) | 2012-11-22 |
| ES2392964T3 (en) | 2012-12-17 |
| NZ535810A (en) | 2007-11-30 |
| PL215579B1 (en) | 2013-12-31 |
| US20050163853A1 (en) | 2005-07-28 |
| CN1646171B (en) | 2010-05-26 |
| EP1499361A1 (en) | 2005-01-26 |
| WO2003089008A1 (en) | 2003-10-30 |
| KR101121675B1 (en) | 2012-03-13 |
| PL371595A1 (en) | 2005-06-27 |
| RU2004133887A (en) | 2005-10-20 |
| KR20040103968A (en) | 2004-12-09 |
| CO5611168A2 (en) | 2006-02-28 |
| IL164627A (en) | 2009-11-18 |
| EP1499361B1 (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2484100A1 (en) | Novel biomaterials, their preparation and use | |
| US4894232A (en) | Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base | |
| US5064655A (en) | Liposome gel composition and method | |
| US6448233B1 (en) | Topical application of a combination of benzoyl peroxide and a second active ingredient | |
| JP5203472B2 (en) | Re-epithelialized pharmaceutical composition comprising xanthan gum | |
| WO2006067608A1 (en) | Aqueous formulations based on sodium hyaluronate for parenteral use | |
| KR860001801B1 (en) | Method for preparing anti-inflamatory composition | |
| EP1782816B1 (en) | Water-based medicinal composition containing azithromycin and method of preparing the same | |
| NZ258442A (en) | Preparation of tablets containing various bisphosphonic acid derivatives | |
| JPH11510480A (en) | Compositions and methods for stabilizing polymers | |
| CN1264298A (en) | Bright white film coatings and film coating compositions therefor | |
| JP2003520240A (en) | Parenteral pharmaceutical composition containing biphosphonate | |
| JP2002332248A (en) | G-rich alginic acid-containing composition | |
| EP1940339B1 (en) | Dental implant and production method for said implant | |
| SK288111B6 (en) | Dermatological formulations | |
| JP4752987B2 (en) | External preparation composition | |
| FR2497669A1 (en) | PHARMACEUTICAL PREPARATION HAVING EXCELLENT ABSORPTION PROPERTIES | |
| JP3050898B2 (en) | Aqueous pharmaceutical preparation | |
| IE47833B1 (en) | Process for solubilizing an insoluble drug and an aqueous solution prepared by this process | |
| NZ508888A (en) | Cyclophosphamide coated tablets having no preswollen starch | |
| JP2003128557A (en) | Glucosamine-containing cataplasm | |
| EP0162007A1 (en) | Stable and durable insulin preparation for Acne vulgaris treatment | |
| JP2003528026A (en) | Composition containing dextrin for inhibiting surgical adhesions | |
| JPH10338638A (en) | Preparation for damaged skin restoration | |
| CN1142782C (en) | Dexamethasone gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160418 |